about
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AA critical appraisal of one-stage and chromogenic assays of factor VIII activity.Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.Managing Haemophilia for Life: 5th Haemophilia Global Summit.BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
P2860
Q28075081-213E6824-A8B2-4DFA-B590-D07495C9C966Q38668506-163A46E0-3771-44E6-8E85-03586FB643BCQ38894174-212C2CAE-F95D-4654-9168-B536D777F712Q39648285-F58EF018-86FA-4DD3-9367-35A71E460D5BQ39898980-A1ED00DA-B2E2-42FB-A074-B22FB13F3D89Q40185654-7686CF6A-2E5F-4C87-BE9F-95EE59C4A53AQ44576554-3356532D-BBFA-474D-B51F-8D9AE00DC884Q45004372-2AD5DF08-7B05-416C-8AAB-46FA2B3F4657Q45864807-0A914AB7-B0A7-41FE-87ED-1ED968E5947AQ45866709-FB499339-680B-4CF4-9F00-DFAF8E0EE34EQ45870406-742E40B8-8F84-453D-A660-E81961C10DC7Q45872443-E824301A-D5D3-43D7-AE7C-E4B82651AA74Q45875490-FB7C4A7F-D2BE-4084-90E4-2F4D56FB5D5DQ45879098-AAE48D5C-757D-4DEC-AC85-39484FC6ED98Q45884519-D2099D9E-4DEF-4EF1-B804-D2D61F668056Q45885298-7624263F-55AD-4D56-A41B-A5CD5BA32609Q45885882-609683F0-2D21-417F-BB0C-2B9F1636584E
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Monitoring of modified factor VIII and IX products.
@en
type
label
Monitoring of modified factor VIII and IX products.
@en
prefLabel
Monitoring of modified factor VIII and IX products.
@en
P2093
P2860
P356
P1433
P1476
Monitoring of modified factor VIII and IX products.
@en
P2093
P2860
P356
10.1111/HAE.12423
P478
20 Suppl 4
P577
2014-05-01T00:00:00Z